Skip navigation

Action Plan Strategies for Long Term Success

January 22-23, 2019
  • Alexandria, VA

Industry Update —
FDA Releases Biosimilar Action Plan: Balancing Innovation and Competition – July 2018
Navigate Evolving Regulations  •  Educate Stakeholders
Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that pharmaceutical companies develop strategies to navigate evolving regulations, educate stakeholders in cross functional areas and execute long-term decisions to prepare for success. At CBI’s 14th Biosimilars Summit, you’ll gain insights from industry experts on the tools and strategies needed to prepare for the current changes impacting all elements of the healthcare industry.

Hear insights from key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing everything from navigating impending regulations, determining optimal pricing models, accelerating market access strategies and executing strategic, long term decisions to mitigate risk and build for success.

Join CBI’s 14th Biosimilars Summit and explore the current global climate for biosimilars, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market.

Hear Expert Insights On:

  • The FDA’s Biosimilar Action Plan and streamlining further for success
  • Leveraging Real World Evidence in the US Biosimilars Market
  • The latest in Biosimilar News
  • Optimizing the Value of Employers
  • Shrinking the Education Gap on Biosimilars across cross functional areas
  • Payer insights on rebate challenges, biosimilar adoption and reimbursement
  • Commercial Considerations and Market Access for New Launches
  • Opportunities for the Global Development of Biosimilars
  • HCPCS Biosimilar J-Codes impact on reimbursement and pricing
  • And more!

Previous Attendee Acclaim:

Best Biosimilars conference going in the U.S.

Another excellent CBI Biosimilar conference. Topical. Interesting. Engaging. Smoothly run…Agenda stays
topical with the times. Thank you.

This is truly one of my favorite conferences because of the level of engagement from the audience throughout.

14th Biosimilars Summit

Action Plan Strategies for Long Term Success

Industry Update —
FDA Releases Biosimilar Action Plan: Balancing Innovation and Competition – July 2018
Navigate Evolving Regulations  •  Educate Stakeholders
Accelerate Market Access

As more biosimilar products continue to be added to the FDA pipeline, it is critical that pharmaceutical companies develop strategies to navigate evolving regulations, educate stakeholders in cross functional areas and execute long-term decisions to prepare for success. At CBI’s 14th Biosimilars Summit, you’ll gain insights from industry experts on the tools and strategies needed to prepare for the current changes impacting all elements of the healthcare industry.

Hear insights from key stakeholders including biosimilar and innovator pharmaceutical manufacturers, payers, providers and patient advocates addressing everything from navigating impending regulations, determining optimal pricing models, accelerating market access strategies and executing strategic, long term decisions to mitigate risk and build for success.

Join CBI’s 14th Biosimilars Summit and explore the current global climate for biosimilars, evaluate competition and benchmark with industry peers on how to navigate the changing regulations and landscape of the biosimilars market.

Hear Expert Insights On:

  • The FDA’s Biosimilar Action Plan and streamlining further for success
  • Leveraging Real World Evidence in the US Biosimilars Market
  • The latest in Biosimilar News
  • Optimizing the Value of Employers
  • Shrinking the Education Gap on Biosimilars across cross functional areas
  • Payer insights on rebate challenges, biosimilar adoption and reimbursement
  • Commercial Considerations and Market Access for New Launches
  • Opportunities for the Global Development of Biosimilars
  • HCPCS Biosimilar J-Codes impact on reimbursement and pricing
  • And more!

Previous Attendee Acclaim:

Best Biosimilars conference going in the U.S.

Another excellent CBI Biosimilar conference. Topical. Interesting. Engaging. Smoothly run…Agenda stays
topical with the times. Thank you.

This is truly one of my favorite conferences because of the level of engagement from the audience throughout.